RxLaw launches in Ontario, offering specialized legal support for pharmacists

Aly Háji, a prominent Ontario lawyer known for representing pharmacists, launched his own boutique law firm, RxLaw, on Apr. 1, 2025, after departing Toronto-based Ricketts Harris LLP.

Háji, who initially trained as a pharmacist before pivoting to law, says "pharmacists and regulated health professionals need legal support from people who actually understand what it’s like to be in their shoes." Last year he garnered attention representing Ontario pharmacists in a proposed class-action against Loblaw, alleging unethical corporate practices.

Michael Nashat, a director of OnPharm United, a network of more than 600 independent pharmacies, and former chair of the Pharmacy Practice Committee with the province's pharmacy regulator, spoke to Háji’s unique value in the pharmacy world. 

"It's common practice for regulators to retain top legal talent in the field," he says. Nashat pointed out that when a lawyer is retained by the Ontario College of Pharmacists, for example, "they can't take on defense cases on behalf of pharmacists against the College," as doing so would put them in conflict. 

"Instead of having one large client, he's taken an entrepreneurial risk," Nashat says, pointing to Háji's decision to represent pharmacists rather than regulatory bodies exclusively.

Currently, Háji is involved in shaping the regulation of Preferred Provider Networks (PPNs). In a recent analysis commissioned by OnPharm United, RxLaw identified significant flaws in proposed regulations by the Ontario College of Pharmacists intended to address patient autonomy issues associated with PPNs. 

Háji says pharmacists are increasingly exposed to significant regulatory risks stemming from the adoption of AI in pharmacy practice, as well as their expanding roles. 

Across the country, pharmacists are being asked by provinces to fill primary healthcare gaps, taking on the management of complex patients and the ability to prescribe. Háji says the uncharted legal risks that come with an expanded scope are "the most pressing issue for Canada's pharmacists in 2025."

"Our mission is to empower healthcare providers and institutions with practical, proactive guidance," Háji says. "Beyond aggressively defending our clients in audits, investigations, and other regulatory proceedings, we actively advise on anticipating and adapting to shifts in law and policy."

Since announcing RxLaw, Háji, who has a substantial following in Ontario’s pharmacy community, has experienced "overwhelming support from friends, clients, and colleagues."